Evaluating lurasidone as a treatment option for bipolar disorder

References

• Whiteford HA, Ferrari AJ, Degenhardt L, et al. The global burden of mental, neurological and substance use disorders: an analysis from the global burden of disease study 2010. Plos One. 2015;10(2):e0116820.
   PubMed Web of Science ®Google Scholar
• Merikangas KR, Jin R, He JP, et al. Prevalence and correlates of bipolar spectrum disorder in the World mental health survey initiative. Arch Gen Psychiatry. 2011;68(3):241–251.
   PubMed Web of Science ®Google Scholar
• Murphy FC, Sahakian BJ. Neuropsychology of bipolar disorder. Br J Psychiatry. 2001;178(Suppl 41):S120–S127.
   PubMedGoogle Scholar
• Miller S, Dell’Osso B, Ketter TA. The prevalence and burden of bipolar depression. J Affect Disord. 2014;169(Supplement 1):S3–11.
   PubMedGoogle Scholar
• Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171(2):160–168.
   PubMed Web of Science ®Google Scholar
• Loebel A, Cucchiaro J, Silva R, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171(2):169–177.
   PubMed Web of Science ®Google Scholar
• Suppes T, Kroger H, Pikalov A, et al. Lurasidone adjunctive with lithium or valproate for bipolar depression: a placebo-controlled trial utilizing prospective and retrospective enrolment cohorts. J Psychiatr Res. 2016;78:86–93.
   PubMed Web of Science ®Google Scholar
• Fornaro M, De Berardis D, Perna G, et al. Lurasidone in the treatment of bipolar depression: systematic review of systematic reviews. Biomed Res Int. 2017;2017:3084859.
   PubMed Web of Science ®Google Scholar
• Roberts RJ, Lohano KK, El-Mallakh RS. Antipsychotics as antidepressants. Asia-Pac Psychiatry. 2016;8(3):179–188.
   PubMed Web of Science ®Google Scholar
• Ishibashi T, Horisawa T, Tokuda K, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Therap. 2010;334(1):171–181.
   PubMed Web of Science ®Google Scholar
• Przemysław B, Dudek D, Samochowiec J. Towards better non-selectivity: the role of 5-HT7 receptors in therapeutic efficacy of a second-generation antipsychotic, lurasidone. Psychiatr Pol. 2015;49:243–253.
   PubMed Web of Science ®Google Scholar
• Wong DF, Kuwabara H, Brašić JR, et al. Determination of dopamine D₂ receptor occupancy by lurasidone using positron emission tomography in healthy male subjects. Psychopharmacol. 2013;229(2):245–252.
   Web of Science ®Google Scholar
• Meltzer HY, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry. 2011;168(9):957–967.
   PubMed Web of Science ®Google Scholar
• Bressan RA, Costa DC, Jones HM, et al. Typical antipsychotic drugs — D2 receptor occupancy and depressive symptoms in schizophrenia. Schizophr Res. 2002;56(1–2):31–36.
   PubMed Web of Science ®Google Scholar
• Sunovion Pharmaceuticals Inc. Latuda (Lurasidone hydrochloride) package insert. Marlborough (MA): Sunovion Pharmaceuticals Inc; 2013.
   Google Scholar
• Lee K-R, Chae Y-J, Koo T-S. Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats. Xenobiotica. 2011;41(12):1100–1107.
   PubMed Web of Science ®Google Scholar
• Preskorn S, Ereshefsky L, Chiu YY, et al. Effect of food on the pharmacokinetics of lurasidone: results of two randomized, open-label, crossover studies. Hum Psychopharmacol. 2013;28(5):495–505.
   PubMed Web of Science ®Google Scholar
• Citrome L, Ketter TA, Cucchiaro J, et al. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord. 2014;155:20–27.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Cucchiaro J, Pikalov A, et al. Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial. J Clin Psychiatry. 2015;76(4):398–405.
   PubMed Web of Science ®Google Scholar
• Swann AC, Fava M, Tsai J, et al. Lurasidone for major depressive disorder with mixed features and irritability: a post-hoc analysis. CNS Spectr. 2017;22(2):228–235.
   PubMed Web of Science ®Google Scholar
• Calabrese J, Rajagopalan K, Ng-Mak D, et al. Effect of lurasidone on meaningful change in health-related quality of life in patients with bipolar depression. Int Clin Psychopharmacol. 2016;31(3):147–154.
   PubMed Web of Science ®Google Scholar
• Rajagopalan K, Bacci ED, Ng-Mak D, et al. Effects on health-related quality of life in patients treated with lurasidone for bipolar depression: results from two placebo controlled bipolar depression trials. BMC Psychiatry. 2016;16:157.
   PubMed Web of Science ®Google Scholar
• Chapel S, Chiu -Y-Y, Hsu J, et al. Lurasidone dose response in bipolar depression: a population dose-response analysis. Clin Therap. 2016;38(1):4–15.
   PubMed Web of Science ®Google Scholar
• Duru G, Fantino B. The clinical relevance of changes in the montgomery-asberg depression rating scale using the minimum clinically important difference approach. Curr Med Res Opin. 2008;24(5):1329–1335.
   PubMed Web of Science ®Google Scholar
• Yatham LN, Mackala S, Basivireddy J, et al. Lurasidone versus treatment as usual for cognitive impairment in euthymic patients with bipolar I disorder: a randomised, open-label, pilot study. Lancet Psychiatry. 2017;4(3):208–217.
   PubMed Web of Science ®Google Scholar
• Sajatovic M, Ng-Mak D, Solem CT, et al. Dosing patterns and medication adherence in bipolar disorder patients treated with lurasidone: a US retrospective claims database analysis. Ther Adv Psychopharmacol. 2016;6(6):355–368.
   PubMed Web of Science ®Google Scholar
• Ng-Mak D, Halpern R, Rajagopalan K, et al. Hospitalization risk in bipolar disorder patients treated with lurasidone versus other atypical antipsychotics. Curr Med Res Opin. 2019;35(2):211–219.
   PubMed Web of Science ®Google Scholar
• Ketter TA, Sarma K, Silva R, et al. Lurasidone in the long-term treatment of patients with bipolar disorder: a 24-week open-label extension study. Dep Anxiety. 2016;33(5):424–434.
   PubMed Web of Science ®Google Scholar
• Pikalov A, Tsai J, Mao Y, et al. Long-term use of lurasidone in patients with bipolar disorder: safety and effectiveness over 2 years of treatment. Int J Bipolar Disord. 2017;5(1):1–8.
   PubMedGoogle Scholar
• Calabrese JR, Pikalov A, Streicher C, et al. Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder. Eur Neuropsychopharmacol. 2017;27(9):865–876.
   PubMed Web of Science ®Google Scholar
• Miller S, Do D, Gershon A, et al. Longer-term effectiveness and tolerability of adjunctive open lurasidone in patients with bipolar disorder. J Clin Psychopharmacol. 2018;38(3):207–211.
   PubMed Web of Science ®Google Scholar
• Findling RL, Goldman R, Chiu -Y-Y, et al. Pharmacokinetics and tolerability of lurasidone in children and adolescents with psychiatric disorders. Clin Therap. 2015;37(12):2788–2797.
   PubMed Web of Science ®Google Scholar
• DelBello MP, Goldman R, Phillips D, et al. Efficacy and safety of lurasidone in children and adolescents with bipolar I depression: a double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry. 2017;56(12):1015–1025.
   PubMed Web of Science ®Google Scholar
• Sajatovic M, Forester BP, Tsai J, et al. Efficacy of lurasidone in adults aged 55 years and older with bipolar depression: post hoc analysis of 2 double-blind, placebo-controlled studies. J Clin Psychiatry. 2016;77(10):e1324–e1331.
   PubMed Web of Science ®Google Scholar
• Forester BP, Sajatovic M, Tsai J, et al. Safety and effectiveness of long-term treatment with lurasidone in older adults with bipolar depression: post-hoc analysis of a 6-month, open-label tudy. Am J Geriatric Psychiatry. 2018;26(2):150–159.
   PubMed Web of Science ®Google Scholar
• Pacchiarotti I, Murru A, Kotzalidis GD, et al. Hyperprolactinemia and medications for bipolar disorder: systematic review of a neglected issue in clinical practice. Eur Neuropsychopharmacol. 2015;25(8):1045–1059.
   PubMed Web of Science ®Google Scholar
• Howland RH. Update on newer antipsychotic drugs. J Psychosoc Nurs Ment Health Serv. 2011;49(4):13–15.
   Web of Science ®Google Scholar
• De Hert M, Yu W, Detraux J, et al. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone, and paliperidone in the treatment of schizophrenia and bipolar disorder. CNS Drugs. 2012;26(9):733–759.
   PubMed Web of Science ®Google Scholar
• Meyer JM, Ng-Mak DS, Chuang CC, et al. Weight changes before and after lurasidone treatment: a real-world analysis using electronic health records. Ann Gen Psychiatry. 2017;16:36.
   PubMed Web of Science ®Google Scholar
• Rafi M, Goyal C, Reddy P, et al. Lurasidone induced thrombocytopenia: is it a signal of drug induced myelosuppression? Ind J Psychol Med. 2018;40(2):191–192.
   PubMedGoogle Scholar
• El-Mallakh RS. Receptor occupancy and drug response: understanding the relationship. Curr Psychiatry. 2018;17(9):1–6.
   Google Scholar
• Voruganti LP, Awad AG. Is neuroleptic dysphoria a variant of drug-induced extrapyramidal side effects? Can J Psychiatry. 2004 May;49(5):285–289.
   PubMed Web of Science ®Google Scholar
• Bo Q, Mao Z, Li X, et al. Use of the MATRICS consensus cognitive battery (MCCB) to evaluate cognitive deficits in bipolar disorder: a systematic review and meta-analysis. PLoS One. 2017;12(4):e0176212.
   PubMed Web of Science ®Google Scholar
• Canale V, Partyka A, Kurczab R, et al. Novel 5-HT7R antagonists, arylsulfonamide derivatives of (aryloxy)propyl piperidines: add-on effect to the antidepressant activity of SSRI and DRI, and pro-cognitive profile. Bioorg Med Chem. 2017;25(10):2789–2799.
   PubMed Web of Science ®Google Scholar